‘Drug hunter’ deploys AI to accelerate path to new therapies
When Tim Heffernan, Ph.D., arrived at MD Anderson in 2011, he saw an opportunity to fundamentally change how cancer drugs are developed. With experience spanning academia and the biopharmaceutical sector, he recognized that the traditional model — years of siloed trial and error — needed transformation.
Heffernan, a self-described “drug hunter,” now leads this change as vice president and head, Oncology Research and Development...
